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Abstract
Analysis of microarray and other high throughput data often involves identification of genes consistently up or down-
regulated across samples as the first step in extraction of biological meaning. This gene-level paradigm can be limited as a
result of valid sample fluctuations and biological complexities. In this report, we describe a novel method, SLEPR, which
eliminates this limitation by relying on pathway-level consistencies. Our method first selects the sample-level differentiated
genes from each individual sample, capturing genes missed by other analysis methods, ascertains the enrichment levels of
associated pathways from each of those lists, and then ranks annotated pathways based on the consistency of enrichment
levels of individual samples from both sample classes. As a proof of concept, we have used this method to analyze three
public microarray datasets with a direct comparison with the GSEA method, one of the most popular pathway-level analysis
methods in the field. We found that our method was able to reproduce the earlier observations with significant
improvements in depth of coverage for validated or expected biological themes, but also produced additional insights that
make biological sense. This new method extends existing analyses approaches and facilitates integration of different types
of HTP data.
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Introduction
Although the use ofDNAmicroarraysand otherhigh throughput
(HTP) technologies is increasingly widespread and affordable,
identifying the underlying biological themes from HTP data
remains a major challenge in the arena of systems biology. Once
data from these experiments has been normalized, a tremendous
variety of software tools and methods are available for analysis of
HTP data, primarily focusing on microarray data. These methods
primarily rely on several categories of common gene-level
approaches. One category of approaches is gathering patterned
genes across samples or datasets by clustering (e.g., hierarchical [1],
K-means [2], or SOM [3] methods, pattern extraction method [4]);
Another category of common approaches is generating differenti-
ated gene lists from two or more class contrasts using a variety of
methods (Significance Analysis of Microarray [5], moderated t-test
[6–7], LPE [8], FDR [9], as well as other gene selection methods
including ‘‘unusual ratio method’’ [10], analysis of variance
(ANOVA) related methods [11–16], Mixed Model Analysis [17].
A more recent approach, namely meta-analysis, looks for common
signatures across multiple independent datasets by combining
multiple statistical methods including simple t-test, FDR, and cross-
validation into a single result [18].
In order to identify the biological themes embedded in such
differentiated gene lists, the next step typically maps these genes to
their pathways or networks. Further integration of this data with
literature resources connects the identified genes with their
potential biological roles [4,19], www.ingenuity.com, www.gen-
ego.com. Alternatively, enrichment-based analysis [4,20–22] can
be applied to such a gene list to generate ranked functional
categories (e.g., GO) or pathways based on their enrichment levels,
so that the significantly enriched pathways and their associated
genes can be easily identified as the primary biological themes.
Additional efforts have been made using various algorithms and
statistical methods for gene set-based group testing analysis [23–
27]. Some very recent efforts explore the topology and
architectures of the networks in conjunction with high-throughput
data to seek biological scenarios [28–29].
The existence of high levels of natural variation within
populations coupled with the observation that very slight changes
in multiple relevant genes in a gene set can trigger biological
changes has led to the development of several gene-set based or
group testing methods: 1. over-representation analysis (ORA)
[4,20–22,30]; 2. functional class scoring (FCS) [23–24,27,31–33];
3. global tests [34]; 4. module-level analysis scheme [35–37]; 5.
singular value decomposition or SVD-based method [38]; 6. a
network structure-based method [39].
Most, if not all of these methods directly use cross-sample
evaluation for differentiated genes or ranking genes for further
gene-set based methods, based on the assumption that, for a given
phenotype (e.g. tumor vs. normal tissues, treated vs. control), any
relevant genes should behave consistently across the samples or
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Tumor or normal tissues). With existing group-test analysis methods
such as GSEA [23–24], the assertion is made that in order to be
significant, the data distribution per gene is significantly shifted
between the contrasted classes. However, we challenge this notion
with a new more general assertion that while biologically relevant
genes may consistently behave in correlation with an associated
phenotype across a population, it is even more likely that common
pathways can be impacted through distinct gene events that are not
reflected at the individual gene level across samples. Such pathway-
level consistency seems particularly relevant considering the
stochastic nature of many epigenetic events that lead to disease
states. For example, a conventional t-test based approach is usually
used to evaluate the statistical difference of genes among the
individuals between two contrasted classes for a typical microarray
dataset. For a specific gene, even with a statistically significant p-
value,the expression ofthis gene inoneormore samples ofone class
could have the same or even lower value than some samples from
the other class, although the mean of expression for this gene in the
first class is higher than that of the second one with statistical
significance suggested by p-value. Thus, with the presence of such
sample-level variants, this gene will still be considered as a
differentiated gene and become included in the final differentiated
gene list because it may have passed statistical criteria including p-
value or FDR. This is a result of the fact that all variances of
individual gene levels are aggregated into a single decision:
differentiated gene or a single measurement: fold change or p-
value. However, as we will discuss below, such sample-level variants
or specificity in a class population, although some would be more
common and some would be unique, can be both realistic and
biologically relevant, since even for this same phenotype, other
relevant genes could have changed or other types of changes for this
gene, such as phosphorylation status or protein stability, which
could not be captured by microarray, could happen in this
individual. This may otherwise mask the real effect leading to the
same or a similar phenotype. In short, multiple genes within a
biological pathway could be impacted with the same net-effect on
the pathway. Therefore what may be happening at a higher
biological level (i.e., group of relevant genes, gene sets, pathways,
functionally related genes) may have been excluded from the
analysis if such sample-level specificity is not taken into account.
In order to capture the sample-level specificity of gene-level
variance, we introduce a new concept - sample-level differentiated
genes (SLDGs). These are defined as genes that are differentially
expressed for a sample in one class when compared to the data
distribution of the other class population. We believe that this new
concept should accommodate both the gene-level changes
identified by established methods but also sample-level specific
changes related to the phenotype but only evident in individual
samples. Although variations and even outliers that can be
introduced by technical issues or experimental variations that have
nothing to do with biological relevance, the chance that multiple
related genes in a pathway or biological process have such issues
simultaneously should be rare. Thus, SLDGs for each sample can
be used as individual gene lists to evaluate the data consistency at
the pathway-level using an ORA-like enrichment method. Instead
of using summarized differentiated gene lists, SLDG lists are used
to calculate enrichment levels of each term for each sample and a
class-contrast based pathway-ranking method is then used to rank
the most consistent and enriched pathways (or gene sets, GO
terms). We named this method Sample-Level Enrichment-based
Pathway-Ranking method (SLEPR).
In this report, we provide evidence that analyzing data at the
level of functional categories, including well-defined or customized
pathways and GO terms, for pathway-level consistency, may help
understand the underlying biological themes at a higher level or in
more detail than other methods provide. Furthermore, in addition
to identifying potential biologically relevant processes or pathways,
we also look for pathway-level differentiated genes from sample-
level differentiated gene lists, which can be combined among
sample populations to reveal a whole spectrum of genetic and
biochemical changes associated with the phenotype in question. In
contrast to conventional methods, we have extended the
‘‘differentiated’’ concept from the gene-level to the pathway-level,
so that one can focus on a biological process or pathway that has
consistent changes at the pathway-level rather than just individual
gene-level across the samples or datasets in a study.
As a proof of concept, we have used this method to analyze
several public microarray datasets with validated results and/or
expected biological themes. We have found that the SLEPR
method effectively reproduced the previously analyzed and
experimentally validated results or generated analysis results that
are consistent with biologically relevant expectations. In direct
comparison with the GSEA method, we also found that the
SLEPR method uncovered many other potentially biologically
relevant pathways not identified by GSEA including many sample-
specific genes that potentially cover the entire repertoire of
candidate genes for pathways or gene sets that are associated with
the expected phenotype. We hope that these results give a more
complete picture of phenotype-wise genetic and biochemical
changes and that this method will help derive biological themes
from additional datasets measuring changes at different levels of
regulation including transcription, protein expression, and phos-
phorylation when these data become increasingly available in the
future.
Results
Overview: Sample-Level Enrichment-Based Pathway
Ranking Method (SLEPR)
To overcome the issues and limitations of the gene-level
consistency paradigm where data analysis primarily considers the
change in gene behavior (e.g., expression) that consistently occurs
in the majority of the sample population, we devised a simple
approach, namely Sample-Level Enrichment-Based Pathway
Ranking Method (SLEPR), which is schematically illustrated in
Figure 1 and described in more detail in the methods section. One
of the major goals of the SLEPR method is to consider sample-
level specificity for gene-level variances, and place the identified
genes in the context of a priori defined gene sets, annotated
biological processes or pathways, functional categories (e.g., GO
terms) and look for pathway-level consistency of enrichment effects
from changes occurring at multiple related genes systematically.
The goal is to accomplish this objective without sacrificing
sensitivity in detecting those genes that do behave consistently
within their class.
Using a recent diabetes study and their class contrast (e.g., highly
expressed in individuals with NGT versus those with DM2: [23]), we
first derived sample-level differentiated genes for each sample based
on the data distribution of samples from the Exclusion/Background
class using MADe-based statistics (Figure 1). The null hypothesis for
SLEPRis that sample-level differentiated gene lists are random sets of
genes with regard to their belonging to a particular sample group in a
given class contrast. The alternative hypothesis is that sample-level
differentiated genes are associated with the specific class assignment
and therefore the biological phenotype under study. We also chose to
allow the concept of the gene group to remain arbitrary and thus can
include conventional gene sets, pathways, functional categories such
SLEPR Pathway Ranking Method
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binding site and we will simply refer to these groups as gene sets
henceforth. As a consequence, pathway-level consistent enrichment
of genes annotated in a gene set within each of these sample-level
differentiated gene lists would be biologically relevant to the
phenotype being contrasted in the classes under study.
We then determine the functional enrichment levels in any ap r i o r i
defined gene sets for each derived sample-level differentiated gene list.
The derived enrichment scores are used to evaluate the pathway-level
consistency of enrichment for gene sets using a pathway-ranking
algorithm in the SLEPR method. The method considers both the
positive contribution of class I (included) and the negative
Figure 1. Schematic overview of SLEPR method (see Materials And Methods section for more details). The goal of SLEPR method is to
use sample-level differentiated genes for each sample to capture the sample-level specificity for gene-level variance, and then use functional
enrichment levels of these gene lists to evaluate pathway-level data consistency associated with the contrasted classes in study: Inclusion/Target
class versus Exclusion/Background class (e.g., NGT versus DM2+IGT in the human type 2 diabetes mellitus (DM2) study [23]). Step 1 of SLEPR is to
assign the samples to the Inclusion class (I) and Exclusion class (E). Then for each genes or features in study (i.e., G1, G2, G3…Gn), consider the data
distribution and use median and MADe of data in samples of class E to set up the cutoff for sample-level differentiated genes for each genes (Step 2).
Each gene Gi will have its own cutoff to determine if it is a sample-level differentiated gene. Gene Gi will be selected as the sample-level differentiated
gene for a sample if the data of gene Gi in this sample is beyond the cutoff (Step 3). Each sample including samples from both I and E classes will
have its own sample-level differentiated gene list (L1, L2, L3….) (Step 3). To determine the functional enrichment levels in any a priori defined gene
sets, pathways, or functional categories (e.g., GO terms) for each of the sample-level differentiated lists, batch computation of Fisher’s exact test
based enrichment analysis is performed and the results are merged automatically into a matrix (e.g., Stanford format file) of enrichment scores which
consists of enrichment scores of each sample from class I and E for each term (T1, T2, T3, …Tm), which are transformed as 2log10(p-value) of Fisher’s
exact test p-values (Step 4). To determine whether a gene set, pathway, or functional category (e.g., GO term) is significant in terms of how consistent
it is enriched across samples, a pathway ranking algorithm is applied to the enrichment score matrix to obtain pathway ranking scores, which
considers both positive contribution of class I and negative contribution of class E from individual sample-level enrichment level (see details in
Materials And Methods section) (Step 5). To determine the statistical significance of actual ranking of a gene set or a GO term in the contrasted
classes: I versus E, the entire procedure (steps 1 to 5) is repeated 1000 times or more by simply permutating the class labels for each selected samples
(Step 6). The pathway ranking scores of each term from each permutation are pooled together and used to build the empirically derived distribution
of pathway ranking scores from the permutation procedure. The permutated p-value for each term is calculated as the fraction of random trials
resulting in permutated pathway ranking scores higher than the actual score from the original sample assignments.
doi:10.1371/journal.pone.0003288.g001
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enrichment. This is done in order to reduce possible bias by using
onlysamplesfromtheExclusionclassasthereferencebackgroundfor
cutoff determination for sample-level differentiated genes.
Case Study 1: Human Diabetes Datasets
The human type 2 diabetes mellitus (DM2) dataset described
previously [23] consists of 22,000 genes in skeletal muscle biopsy
samples from 43 age-matched males: 17 with normal glucose
tolerance (NGT), 9 with impaired glucose tolerance (IGT) and 17
with DM2. A goal of the original study [23] was to identify gene
expression changes characteristic of DM2 and pre-defined gene
sets for association with the disease phenotype. A novel method,
called Gene Set Enrichment Analysis (GSEA), was developed to
successfully identify as significant a set of genes involved in
oxidative phosphorylation, although none of the individual genes
had a significant difference in expression between the diagnostic
categories [23]. Although GSEA successfully identified oxidative
phosphorylation as one of major biological themes associated with
the disease phenotype, subsequent studies revealed that the GSEA
method was biased toward assigning higher enrichment scores to
gene sets of large size [40].
In order to compare methods, we applied the SLEPR method to
the same microarray dataset from the human type 2 diabetes
mellitus study [23]. To ensure a fair comparison, we also
implemented into the SLEPR method the same GSEA annotation
database (also call MSigDB) [24] and compared the analysis
results for the same database of gene sets.
For each single gene in our SLEPR method, we used the
Exclusion/Background class as the background or reference
distribution of data. In contrast to GSEA-based methods, instead
of looking at the change in expression of genes between the two
contrasted classes, our SLEPR method starts with sample-level
differentiated genes by comparing data of each sample to the data
distribution of samples of the Exclusion class. Thus, the expression
of each gene from each individual sample (samples from both
Inclusion and Exclusion classes) is compared to this background
distribution of the same genes’ expression and is defined as a
sample-level differentiated gene for a sample if the expression of
this gene in the corresponding sample has an expression level at a
distance larger than MADe compared to the median of
background data range for this gene from either one or both
directions (see Materials And Methods section).
We used the NGT samples as the Inclusion class and IGT and
DM2 samples together or DM2 samples only as our Exclusion
class (see Materials And Methods section for class definition) and
used GSEA annotations of gene sets or MSigDB (http://www.
broad.mit.edu/gsea/) for SLEPR (Table 1, 2) and GSEA analysis
(Table 3, 4). Our SLEPR method successfully identified 5 closely
related terms: ‘‘mitochondrial genes’’ (two of them, annotated
from different sources), ‘‘electron transport’’, and ‘‘oxidative
phosphorylation’’, ‘‘PGC related genes’’ at the top of the ranked
term list using either IGT+DM2 or only DM2 samples as
Exclusion class (Table 1, 2), which is consistent with the previous
analysis result of GSEA [23]. Particularly when both IGT and
DM2 samples are used, these relevant terms appear to be even
more significant and ranked as the top 5 terms (Table 1). However,
the GSEA method only ranked 3 of these terms among the top list
when using only DM2 samples as the Exclusion class (Table 4),
and only one of these terms among the top list when using both
IGT and DM2 samples as Exclusion class (Table 3). Thus, the
SLEPR method appears to uncover more terms with expected
biological relevance with higher significance scores than GSEA in
both settings of class comparison, especially when both IGT and
DM2 samples were pooled together as one class (Table 1, 3). The
additional terms uncovered by SLEPR: ‘‘mitochondrial genes’’
and ‘‘PGC related genes’’, which were absent from the GSEA
results and have strong biological relevance with the previously
identified and validated term ‘‘oxidative phosphorylation’’: the
mitochondria are well known as the cellular compartment where
the oxidative phosphorylation reactions occur and PGC (or PGC-
1)-responsive genes involved in oxidative-phosphorylation are
coordinately downregulated in human diabetes [23]. The fact that
these additional terms are closely related to electron transport and
oxidative phosphorylation, suggests that SLEPR could potentially
uncover more related biological themes, presumably due to our
consideration of sample-level specificity for gene-level variances
and pathway-level consistency across the population.
Interestingly, for many of the relevant terms identified by both
SLEPR and GSEA, SLPER revealed a higher significance
compared to GSEA in general. For example, although both
SLEPR and GSEA detected ‘‘oxidative phosphorylation’’ as a top
ranked term, the permutated p-values of ‘‘oxidative phosphoryla-
tion’’ derived from SLEPR (p=0.00048 or p=0.00034, Table 1
and 2) appear to be more significant than the GSEA method
(p=0.029 from original GSEA analysis [23], p=0.02 with current
version (v2.0.1) of GSEA) (Table 4) comparing NGT with only
DM2 samples, and p=0.3511 comparing NGT with both DM2
and IGT samples, which is not significant and ranked only at 165
(Table 3 and see the complete list of the result in Table S1). This
Table 1. Top ranked GSEA annotation terms in SLEPR Analysis Result for Comparison of NGT vs DM2+IGT in human DM2 data.
GSEA_TermName GSEA_TermID Combined Ranking Permutated P_Val FDR q_Val
Mitochondrial genes HUMAN_MITODB_6_2002 1.009408 0.00011557 0.144
Mitochondrial genes MITOCHONDRIA 0.96734041 0.00013403 0.0835
Genes involved in electron transport ELECTRON_TRANSPORT_CHAIN 0.73313179 0.00033066 0.13733333
Oxidative Phosphorylation MOOTHA_VOXPHOS 0.63908609 0.00048395 0.15075
PGC related genes PGC 0.41673472 0.00146549 0.3652
RIBOSOMAL_PROTEINS RIBOSOMAL_PROTEINS 0.26145395 0.00456661 0.9483
Microarray data for human type 2 diabetes mellitus (DM2) study [23] was re-analyzed with SLEPR method to compare either NGT versus IGT+DM2 (IGT+DM2 as
Exclusion/Background class in SLEPR). One-side MADe method was used in SLEPR for selection of highly expressed genes as sample-level differentiated genes in the
comparison of NGT versus IGT+DM2. Two-side MADe method was also used for selection of highly and lowly expressed genes as sample-level differentiated genes, and
similar result was obtained (see Table S4). 1000 permutations were performed. Combined_Ranking: Combined ranking scores for terms; Permutated_P_Val: p-value of
terms derived from permutated data; FDR_q_Val: FDR of terms derived from permutated data (see Materials And Methods section for details).
doi:10.1371/journal.pone.0003288.t001
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‘‘oxidative phosphorylation’’: FDR=0.15 or FDR=0.082 from
SLEPR results (Table 1 and 2) compared to those from GSEA
results: FDR=0.446 and FDR=1 (Table 4, S1).
In addition, the top ranked terms in the GSEA results appeared
to have much higher FDR q-values (Table 3, 4) than those
identified with SLEPR. Furthermore, in the SLEPR results, we
observe a sharp rise in FDR q-values from 0.3652 to 0.9483
between terms No. 5 and 6 (Table 1) and from 0.088 to 0.3335
between terms No. 7 and 8 (Table 2), suggesting that these
thresholds might be used to separate the identified terms into high
and low priority groups.
Since SLEPR is designed to uncover additional information
from sample-level enriched genes, we wanted to evaluate how the
top ranked terms are enriched in individual samples. To do this,
we put the matrix of enrichment scores of 17 top ranked GSEA
annotation terms of SLEPR result (Table 1, also see the complete
list of the result in Table S2) into a heatmap for visualization
(Figure 2). As expected, although the majority of NGT samples
have enrichment scores at a significant level, a small portion of
IGT or DM2 samples also have enrichment scores at significant
levels for some terms, which expand to a larger portion of the
samples for lower ranked terms that have relatively higher FDR q-
values (Figure 2, Table S2).
In order to get a more complete picture of the genes that are
involved in the top ranked terms found by the SLEPR method, we
retrieved the pathway-level differentiated genes that are associated
with one of the top ranked terms: ‘‘Oxidative Phosphorylation’’
from Table 1 using the newly developed WPS pipeline interface
for pathway-level pattern extraction, described in a separate
manuscript [4], Yi and Stephens, unpublished work. As expected,
the pathway-level differentiated genes did not display an obvious
gene-level consistency in their relative expression levels across the
sample population even in the same class (Figure S1), although
Table 2. Top ranked GSEA annotation terms in SLEPR Analysis Result for Comparison of NGT vs DM2 in human DM2 data.
GSEA_TermName GSEA_TermID
Combined
Ranking Permutated P_Val FDR_q_Val
Mitochondrial genes HUMAN_MITODB_6_2002 2.33012855 0.0000025 0.003
Mitochondrial genes MITOCHONDRIA 1.19377468 0.0000975 0.0585
PROPANOATE_METABOLISM PROPANOATE_METABOLISM 0.87576134 0.00029917 0.11966667
PGC related genes PGC 0.85709181 0.00031583 0.09475
Oxidative Phosphorylation MOOTHA_VOXPHOS 0.83877765 0.0003425 0.0822
Genes involved in electron transport ELECTRON_TRANSPORT_CHAIN 0.80602325 0.0003875 0.0775
RIBOSOMAL
PROTEINS RIBOSOMAL_PROTEINS 0.73004401 0.00051333 0.088
Downregulated in correlation with overt
Alzheimer’s Disease, in the CA1 region
of the hippocampus
ALZHEIMERS_DISEASE_DN 0.43387443 0.00222333 0.3335
Microarray data for human type 2 diabetes mellitus (DM2) study [23] was re-analyzed with SLEPR method to compare either NGT versus DM2 (DM2 as Exclusion/
Background class in SLEPR). One-side MADe method was used in SLEPR for selection of highly expressed genes as sample-level differentiated genes in the comparison
of NGT versus DM2. 1000 permutations were performed. Combined_Ranking: Combined ranking scores for terms; Permutated_P_Val: p-value of terms derived from
permutated data; FDR_q_Val: FDR of terms derived from permutated data (see Materials And Methods section for details).
doi:10.1371/journal.pone.0003288.t002
Table 3. Top ranked GSEA annotation terms in GSEA Analysis Result for Comparison of NGT vs DM2+IGT in human DM2 data.
GSEA_TermName GSEA_TermID ES NES NOM p-val FDR q-val FWER p-val
Upregulated by expression of mutant MeCP2
(Rett syndrome) vs. wt MeCP2 in fibroblasts
RETT_UP 0.6723 1.830771 0.001** 0.93558 0.56
Granule constituents expressed during mouse
promyelocytic cell line cell differentiation
LIAN_MYELOID_DIFF_GRANULE 0.5568 1.791872 0.002012 0.700521 0.683




0.5402 1.720124 0.016327 0.971015 0.875
Regulated by UV-B light in normal human
epidermal keratinocytes, cluster 8
UVB_NHEK3_C8 0.4442 1.685022 0.001** 1 0.931
Genes involved in electron transport ELECTRON_TRANSPORT_CHAIN 0.3457 1.680579 0.060797 0.863601 0.937
Down-regulated in mycosis fungoides
(cutaneous T-cell lymphoma) T-cells resistant to
IFN-alpha, compared to sensitive parent cell line
IFNALPHA_RESIST_DN 0.5722 1.648226 0.014315 0.980393 0.968
Regulated by UV-B light in normal human
epidermal keratinocytes, cluster 6
UVB_NHEK3_C6 0.4663 1.642358 0.018987 0.885222 0.979
Microarray data for human type 2 diabetes mellitus (DM2) study [23] was re-analyzed with GSEA method (using the newest version (v 2.0.1) GSEA tool [22]) to compare
NGT versus IGT+DM2. 1000 permutations were performed. **: p-value(s) is adjusted to p=1/number of permutation for p=0 according to GSEA manual.
doi:10.1371/journal.pone.0003288.t003
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class (NGT) compared to Exclusion class (IGT+DM2). Interest-
ingly, after ranking these genes with a method similar to a class
difference ranking method used for term ranking (See Materials
And Methods section), many of genes at the top of the ranked list
showed strong relevance with diabetes, and metabolism (Table
S3). Although the higher ranked genes appear to be distributed
with higher frequency in sample population, each of the sample-
level differentiated genes appeared widely varying among the
samples. However, less variance was observed within the top
ranked genes (Figure S2). This is consistent with the previous
observation [23], and explains why common gene-level methods
can not reveal the changes that occurred at pathway-level.
In order to determine how stable the SLEPR method is in terms
of the choice of changed directions of sample-level differentiated
genes and/or class setting, we also used SLEPR with a two-sided
MADe option for highly or lowly expressed genes in NGT samples
compared to DM2 samples for the same class setting (NGT versus
DM2). Consistent with the one-sided MADe result (Table 1, 2), we
found a very similar result with ‘‘Mitochondrial genes’’ (two of
them from different resources: No. 1 and No. 5 terms), ‘‘PGC
related genes’’ (No. 3 term), and ‘‘oxidative phosphorylation’’ as
the top ranked terms in the lists with two-sided MADe options
(highly expressed or lowly expressed in NGT) (Table S4). We also
identified two or more of relevant terms including ‘‘Mitochondrial
genes’’, ‘‘PGC related genes’’, ‘‘Oxidative Phosphorylation’’, and
‘‘Genes involved in electron transport’’ as top ranked terms as well
in many different class contrast settings: NGT versus DM2+IGT
with two-sided MADe; DM2 lower than NGT with one-sided
MADe; DM2+IGT lower than NGT with one-sided MADe; NGT
versus IGT with one-sided MADe (data not shown).
Selection of cutoffs for significance testing in any gene-set
analysis will have a dramatic impact on the number of pathways
identified and the reliability of the results obtained. In order to
determine the impact of the cutoffs for sample-level differentiated
genes on the final SLEPR results, we used a series of different
cutoffs for selection of sample-level differentiated genes for
comparison of permutated p-values and ranks of SLEPR analysis
results for human type 2 diabetes mellitus (DM2) data [23] with
IGT and DM2 samples as the Exclusion/Background class and
with one-side MADe method for highly expressed genes (as above).
We selected the top 5 ranked terms from the original SLEPR
result (Table 1) for comparison of permutated p-values and ranks
for the same terms in SLEPR results with other cutoffs for selection
of sample-level differentiated genes (Table 5). We found that,
unlike the conventional ORA method [31], which usually uses a
gene-level differentiated gene list, the SLEPR method appears to
be quite resistant to the cutoff change effects. For a wide range of
values for cutoffs of sample-level differentiated genes, SLEPR
maintains the main biological themes in its analysis results in that
all the top ranked terms based on the original 16MADe cutoff are
primarily ranked at the top level (most of the terms still remained
at the top level: ranked within the top 10 functional terms and p-
value less than or close to 0.01). This stability is an important
property of the SLEPR method that would be beneficial, especially
for the situation when different HTP samples with dramatically
different dynamic ranges are being analyzed.
To compare how significant the enrichment score of a top
ranked term from SLEPR result is on the DM2 dataset to that of a
gene set by random chance, we generated 2000 randomly selected
gene sets of the same size as the gene set ‘‘Oxidative
Phosphorylation (MOOTHA_VOXPHOS)’’ (80 genes per gene
set) from annotated genes in the GSEA database or MSigDB.
Then the 80 genes of ‘‘Oxidative Phosphorylation’’ were mixed
with the 2000 randomly selected gene sets to build up the synthetic
database for SLEPR analysis using the same human DM2 dataset.
As expected, ‘‘Oxidative Phosphorylation’’ was identified as the
No. 1 top ranked term with FDR q-value as 0.016 when NGT
versus IGT+DM2 class contrast was used, whereas the No. 2
ranked term (PermTerm157) has FDR q-value at as high as 0.502,
indicating a ‘‘gap’’ between the real relevant terms and the
accidental hit of a randomly selected gene set term (Table S5). A
similar result was found using NGT versus DM2 contrast (data not
shown).
Case Study 2: GNF Human Tissue Datasets
We next used the SLEPR method to analyze another public
microarray dataset: Affymetrix U133A tissue expression dataset,
derived from 79 human tissues, from the Genomic Institute of the
Novartis Research Foundation (GNF) and described previously
[41]. In this case, we used both GSEA annotation and GO (gene
ontology) biological processes as the input gene sets for SLEPR
Table 4. Top ranked GSEA annotation terms in GSEA Analysis Result for Comparison of NGT vs DM2 in human DM2 data.
GSEA_TermName GSEA_TermID ES NES NOM p-val FDR q-val FWER p-val
Up-regulated following treatment with Et-743 at any
timepoint in at least 8 of 11 sarcoma cell lines
ET743_SARCOMA_UP 0.4778 1.851262 0.0019455 0.835225 0.416
Oxidative Phosphorylation MOOTHA_VOXPHOS 0.6187 1.844164 0.02 0.460014 0.446
Target genes down regulated by p53 KANNAN_P53_DN 0.6835 1.84351 0.005848 0.309037 0.447
Genes involved in electron transport ELECTRON_TRANSPORT_CHAIN 0.594 1.840375 0.0217822 0.240362 0.46
p-regulated in liver, heart or kidney tissue from
hypophysectomized rats (lacking growth hormone),
compared to normal controls
HYPOPHYSECTOMY_RAT_UP 0.5129 1.776757 0.0040404 0.3918 0.664
Upregulated by expression of mutant MeCP2 (Rett
syndrome) vs. wt MeCP2 in fibroblasts
RETT_UP 0.544 1.697153 0.0179641 0.740229 0.855
Genes down-regulated by LIF treatment (10 ng/ml,
overnight) in AtT20 cells
ABBUD_LIF_DN 0.569 1.682703 0.0226804 0.727445 0.872
OXIDATIVE_PHOSPHORYLATION OXIDATIVE_PHOSPHORYLATION 0.5167 1.653935 0.0459082 0.832665 0.908
Microarray data for human type 2 diabetes mellitus (DM2) study [23] was re-analyzed with GSEA method (using the newest version (v 2.0.1) GSEA tool [22]) to compare
NGT versus DM2. 1000 permutations were performed. **: p-value(s) is adjusted to p=1/number of permutation for p=0 according to GSEA manual.
doi:10.1371/journal.pone.0003288.t004
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specific biological processes that are enriched in testis-related
tissues that were highly ranked in SLEPR analysis when
configured to select testis-related tissues as the Inclusion class
and the other tissues as Exclusion class, using one-sided MADe
method for highly expressed genes. The expected result was
Figure 2. Heatmap of enrichment scores in all samples from NGT versus IGT and DM2 for the top 17 ranked terms of SLEPR result
listed in Table S2. The enrichment scores, which in general derived from Fisher’s exact test p-value using formula (2Log10(p-value)), were floored
to 0 if the ListHits,2 or p-value.0.05. The rows of the heatmap are the ranked terms in the same order as in Table S2 (Top 7 of them shown in
Table 1) from top to bottom with the higher ranks at the top. The gradient of red color in heatmap indicated the enrichment levels.
doi:10.1371/journal.pone.0003288.g002
Table 5. Comparison of SLEPR results using a series of cutoffs for selection of sample-level differentiated genes.
TermName (TermID) 0.5XMADe 0.75XMADe 1XMADe 1.25XMADe 1.5XMADe
p-Value* Rank p-Value* Rank p-Value* Rank p-Value* Rank p-Value* Rank
Mitochondrial genes
(HUMAN_MITODB_6_2002)
0.150 153 3.08E-04 1 1.16E-04 1 6.58E-05 2 1.03E-05 1
Mitochondrial genes (MITOCHONDRIA) 0.170 179 6.38E-04 2 1.34E-04 2 2.22E-05 1 2.31E-05 2
Genes involved in electron transport
(ELECTRON_TRANSPORT_CHAIN)
4.49E-03 7 8.82E-04 4 3.31E-04 3 1.75E-04 3 7.61E-05 4
Oxidative Phosphorylation
(MOOTHA_VOXPHOS)
1.01E-02 9 6.91E-04 3 4.83E-04 4 2.22E-04 4 7.53E-05 3
PGC related genes (PGC) 1.05E-02 10 2.93E-03 6 1.47E-03 5 5.05E-04 6 6.21E-04 7
Comparison of permutated p-values and ranks of SLEPR analysis results of for human type 2 diabetes mellitus (DM2) data [23] with IGT and DM2 samples as Exclusion/
Background class by using a series of different cutoffs (0.5, 0.75,1,1.25,1.56of MADe) for selection of highly expressed genes as sample-level differentiated genes. The
one-side MADe method selecting for highly expressed genes was used (see Materials And Methods section). The top 5 ranked terms from the case of 1XMADe are
selected for comparison of permutated p-values and ranks for the same terms with those derived from other cutoffs. 1000 permutations were performed.
doi:10.1371/journal.pone.0003288.t005
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biological processes in WPS [4], Yi and Stephens, unpublished
work, as shown in Table 6 for GSEA annotations and Table 7 for
GO biological processes. There are two top ranked functional
terms from GSEA annotations (the No. 1 and No. 2 ranked terms)
that are directly related to testis-related gene expression as
obviously described by the terms themselves (Table 6). As a
comparison, the same data was analyzed using the GSEA method
to compare the selected testis-related tissues with other tissues
within the GNF dataset. As shown in Table 8, the top 2 GSEA
terms obtained by GSEA method do not appear to be directly
related to testis-related functions, whereas the same two terms that
were found as the top 2 terms in the SLEPR method were only
ranked as terms 3 and 4, respectively, in the GSEA analysis result.
Interestingly, we also observed that there exists a sharp rise in
FDR q-values from 0.121 to 0.417 in between No. 2 and 3 terms
of GSEA result and in between No. 1 and No. 2 as well (Table 8),
which seems to reduce the significance of No. 3 and 4 terms that
do not appear to be directly relevant to the function of testis. This
observation makes the GSEA result more difficult to interpret in
that the testis-specific terms (No. 3 and 4 terms) appear to be less
significant (Table 8). In contrast, we observed a sharp rise in FDR
q-values from 0.0005 to 0.0437 between term No. 2 and 3 of the
SLEPR result (Table 6) and such a ‘‘gap’’ in SLEPR result may
help distinguish the testis-specific terms (The top 2 terms) from
more generic terms (No. 3, and 4 term) (Table 6)
Similarly, most of the top ranked terms in the SLEPR result
using GO biological processes are related to testis-specific
functions such as spermatogenesis, and male gamete generation
(Table 7). Interestingly, we again observed a sharp rise in FDR q-
values from 0.0002 to 0.044167 in between No. 5 term
(gametogenesis) and No. 6 term (nuclear division). Interestingly,
all of the top 5 terms are testis-specific terms whereas beginning at
No. 6 term, the terms that ranked below are more generic terms,
which suggested a useful FDR ‘‘gap’’ between significant and
insignificant terms that seems to reflect the difference in biological
relevance or specificity. This observation is also evident in a
heatmap of enrichment scores in that these testis-specific
functional terms (The top 5 terms in Table 7) are enriched
consistently and more specifically in testis-related tissues compared
to rest of the tissues in the dataset (Figure 3).
We also asked the same question as to muscle-related tissues in
the data. In contrast to testis, where essentially a single biological
process is performed, we felt that muscle would represent a more
diverse tissue type, since it is involved in more processes. We
expected that muscle-specific functions or processes would be
highly ranked in SLEPR analysis if we chose to select muscle-
related tissues as the Inclusion class and the other tissues as
Exclusion class, and used a one-sided MADe method to include
highly expressed genes as the sample-level differentiated genes. As
expected, we found that the two top ranked terms are muscle-
specific functions in the SLEPR analysis result using GO biological
Table 6. Top ranked terms in SLEPR analysis result for testis-related tissues in GNF dataset.
GSEA_TermName GSEA_TermID Combined_Ranking Permutated_P_Val FDR_q_Val
Genes expressed specifically in human testis tissue HUMAN_TISSUE_TESTIS 25.62201 7.29E-07 0.001
Testis related genes curated from the GNF normal
tissue compendium
TESTIS_EXPRESSED_GENES 24.08417 7.29E-07 0.0005
Cell-cycle dependent genes regulated following
exposure to serum in a variety of human fibroblast
cell lines
SERUM_FIBROBLAST_CELLCYCLE 6.951284 9.56E-05 0.0437
50 top ranked SAM-defined over-expressed genes
in each subgroup__PR
ZHAN_MM_CD138_PR_VS_REST 6.523997 0.000106 0.0365
Microarray data for GNF human tissues study [41] was analyzed with SLEPR method to compare testis related tissues (total 5 testis related tissues selected: Testis Germ
Cells, Testis Interstitial, Testis Leydig Cell, Testis Seminiferous Tubule, Testis) (as Inclusion/Target tissues in SLEPR) to the other tissues (total 74 tissues) (as Exclusion/
Background class in SLEPR) as for GSEA annotated gene sets. In SLEPR method, one-side MADe method for selection of highly expressed genes as sample-level
differentiated genes was used. 1000 permutations were performed.
doi:10.1371/journal.pone.0003288.t006
Table 7. Top ranked GO Biological Processes terms in SLEPR analysis result for testis-related tissues in GNF dataset.
TermName Term Combined_Ranking Permutated_P_Val FDR_q_Val
spermatogenesis GO:0007283 17.21279 6.71E-07 0.0005
male gamete generation GO:0048232 17.21279 6.71E-07 0.0005
sexual reproduction GO:0019953 16.27175 6.71E-07 0.000333
reproduction GO:0000003 16.17275 6.71E-07 0.00025
gametogenesis GO:0007276 13.95838 6.71E-07 0.0002
nuclear division GO:0000280 4.461007 0.000178 0.044167
M phase GO:0000279 4.361697 0.000195 0.041429
Microarray data for GNF human tissues study [41] was analyzed with SLEPR method to compare testis related tissues (total 5 testis related tissues selected: Testis Germ
Cells, Testis Interstitial, Testis Leydig Cell, Testis Seminiferous Tubule, Testis) as Inclusion/Target tissue to the rest of the tissues (74 other tissues) as Exclusion/
Background class for testis-specific GO biological processes, using one-side MADe method for selection of highly expressed genes as sample-level differentiated genes.
1000 permutations were performed.
doi:10.1371/journal.pone.0003288.t007
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we selected are quite divergent in that they include cardiac
myocytes, smooth muscle, heart, and skeletal muscle, which were
selected together as Inclusion class, the divergence among these
tissues might be quite small compared to the divergence among
other tissues, which makes the pathway ranking still favor muscle-
specific terms. This shows another strength of the SLEPR method
in that it may still be able to catch the pathway-level difference
when there is divergence or large variation amongst the samples in
the same phenotypic class. This is useful in that in cases where
sufficient samples are not available from an individual study, they
may be able to be combined with samples from other studies.
Since both testis-related tissues and muscle-related tissues have a
limited number of samples: 5 and 4, respectively, which are only a
small portion of total 79 tissues in the dataset, there is a possibility
that the small number of the samples in the Inclusion class may
cause a bias favorable to the inclusion class. To test this possibility,
we chose a related tissue type with more samples in the dataset to
test whether the sample-size influences the SLEPR method. We
choose neural or brain-related tissues as our Inclusion class with a
total sample size of 24 and other tissues as the Exclusion tissues.
We ran the SLEPR analysis on GO biological processes and used
the one-sided MADe method to include highly expressed genes as
the sample-level differentiated genes. Interestingly, the sample size
of the Inclusion class does not seem to influence the SLEPR result
- the top 4 ranked GO terms are indeed very specific to neural-
related biological processes (Table S6).
As described above, among the several tissue types (e.g., testis,
muscle, neural-related tissues) we have chosen from this human
tissue dataset to test the SLEPR method, every time it successfully
identified many top-ranked terms that are directly relevant to what
is expected from the tissue types that were chosen. In order to
further characterize the pathway-level differentiated genes at the
top of these ranked term lists, we retrieved the associated genes for
the top ranked testis-specific terms (Table 6) or muscle-specific
terms (Table 9) using the new features in the pathway pattern
Table 8. Top ranked terms in GSEA analysis result for testis-related tissues in GNF dataset.
GSEA_TermName GSEA_TermID ES NES NOM p-val FDR q-val FWER p-val
50 most interesting genes upregulated by the
combination of TSA and DAC in at least one of
four pancreatic cancer cell lines, but not in
normal (HPDE) cells
TSADAC_PANC50_UP 0.571787 2.3071 0.001** 0.002 0.004
Up-regulated 2 hours after VEGF treatment in
human umbilical vein endothelial cells
VEGF_HUVEC_2HRS_UP 0.562051 2.01 0.001** 0.077 0.121
Testis related genes curated from the GNF normal
tissue compendium
TESTIS_EXPRESSED_GENES 0.868249 1.8032 0.001** 0.271 0.417
Genes expressed specifically in human testis tissue HUMAN_TISSUE_TESTIS 0.904183 1.7737 0.001** 0.255 0.474
Microarray data for GNF human tissues study [41] was analyzed with GSEA method [23] (Using the newest version (v2.0.1) GSEA tool [24]) to compare testis related
tissues (total 5 testis related tissues selected: Testis Germ Cells, Testis Interstitial, Testis Leydig Cell, Testis Seminiferous Tubule, Testis) to the other tissues (total 74
tissues) as for GSEA annotated gene sets. 1000 permutations were performed. **: p-value(s) is adjusted to p=1/number of permutation for p=0 according to GSEA
manual.
doi:10.1371/journal.pone.0003288.t008
Figure 3. Heatmap of enrichment scores of sample-level differentiated genes of all samples in human GNF tissue dataset [41] for
the top 8 ranked GO biological process terms shown in Table 7. The enrichment scores, which in general derived from Fisher’s exact test p-
value using formula (2Log10(p-value)), were floored to 0 if the ListHits,2 or p-value.0.05. The rows of the heatmap are the terms and columns are
tissue samples from the dataset. The gradient of red color in heatmap indicated the enrichment levels.
doi:10.1371/journal.pone.0003288.g003
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unpublished work. Interestingly, we found that many of pathway-
level differentiated genes associated with these testis-specific or
muscle-specific terms are expressed at relatively higher level in
only a small portion of these selected testis-related or muscle-
related tissues although some genes are highly expressed in other
tissue types. Figure S3 shows the expression patterns of such genes,
which are associated with the top 2 ranked muscle-specific terms
from SLEPR analysis shown in Table 9 (i.e., muscle contraction
and muscle development). This observation suggests that individ-
ual sample-level variations widely exist across the sample
population, even for the genes that are involved in these highly
relevant biological processes. This suggests that the commonly
used gene-level analysis methods may fail to identify such relevant
pathway-level differentiated genes.
Case Study 3: Prostate Cancer Datasets
We also used the SLEPR method to analyze a well studied
prostate cancer microarray dataset: Affymetrix U95a dataset,
derived from 25 human prostate cancer tissues and 9 nonmalignant
tissues described previously [42,43]. In this case, we used both
GSEA annotation and KEGG pathway collections [4]. Interesting-
ly, in our SLEPR analysis for both highly and lowly expressed genes
(two-sided MADe option for SLEPR) (Table 10), we found that the
top ranked functional gene sets from GSEA annotation are
obviouslycancer-relatedincluding:1)‘‘Sixty-sevengenescommonly
upregulated in cancer relative to normal tissue from a meta-analysis
of the OncoMine gene expression database’’ (p=5.43E-7, FDR q-
value=0.00011) and 2) ‘‘Genes highly expressed in hepatocellular
carcinoma with poor survival’’ (p=5.43E-7, FDR q-value=2.94E-
5). Another top ranked gene set: ‘‘Genes up-regulated by MYC in
P493-6 (B-cell)’’ (p=5.43E-7, FDR q-value=3.45E-5), may be also
consistent with the previous observation as to the presence of
varying amount of B-cells within these tumors [42] and the fact that
c-MYC is a proto-oncogene that is commonly activated in a variety
of human tumors and has been shown to promote tumor
angiogenesis [44]. In contrast, in the GSEA analysis result
(Table 11), only two of the top terms were found in the top list:
‘‘Genes up-regulated by MYC in P493-6 (B-cell)’’ (p=0 (actually
p=0.001 based on 1000 permutation according to GSEA manual),
FDR q-value=0.031) and ‘‘Sixty-seven genes commonly upregu-
lated in cancer relative to normal tissue from a meta-analysis of the
OncoMine gene expression database’’ (p=0.004, FDR q-val-
ue=0.058). However, for the third term: Genes highly expressed
in hepatocellular carcinoma with poor survival, GSEA only ranked
it at position 124 in the list with a very low significance level
(p=0.167, FDR q-value=0.467) (Table S7).
We also ran SLEPR analysis using KEGG annotation for this
dataset with both highly and lowly expressed genes (two-sided
MADe option for SLEPR). Surprisingly, we saw a pathway
‘‘Cholera – Infection’’ at the top of the ranked list (Table S8). As
found by others using the same dataset with the conventional
ORA method [43], ‘‘Cholera – Infection’’ is related to tumorgen-
esis since this pathway contains genes such as adenylate cyclase
signaling and phospholipase C that are changed in tumor cells. In
addition, ‘‘Integrin-mediated cell adhesion’’ was found as the next
top ranked pathway (Table S8), which has been suggested as a
target pathway in many other studies to achieve an optimization of
anticancer treatments, probably through interfering with anti-
apoptotic signaling [45] and/or metastasis. However, this pathway
was not found by conventional ORA analysis or gene-level based
analysis [42,43], probably due to the dispersion of the data or a
lack of consistency at the gene-level for genes in this pathway.
Discussion
More and more evidences have shown that conventional gene-
level analysis methods seeking biomarkers or differential genes
encountered limitations and difficulties from both statistical and
biological sides [46–47]. As with the analysis approaches discussed
in the Introduction section, most, if not all of these gene selection
methods consider the global behavior of individual genes across
the sample population in one class compared to another class as
the basis for grouping by applying various statistics including fold
change, p-value and FDR. The genes associated with the
phenotype of interest that behave more consistently within both
sides of the contrasted classes will be favorably selected as
differential genes and pursued in follow-up studies. The assump-
tion that the most critically involved genes tend to behave in a
similar way between samples within each class is well founded in
many cases, especially for single genes that cause rare diseases.
However, the inherent complexity of biological systems, the
multiple stages where protein function can be regulated, and the
Table 9. Top ranked GO Biological Processes terms of SLEPR result for muscle-related tissues in GNF dataset.
TermName Term Combined_Ranking Permutated_P_Val FDR_q_Val
muscle contraction GO:0006936 5.035783 0.000195 0.289
muscle development GO:0007517 3.766843 0.000438 0.325
cell-cell signaling GO:0007267 3.115529 0.000755 0.373667
morphogenesis GO:0009653 2.51698 0.001281 0.47525
development GO:0007275 2.509388 0.001292 0.3836
organogenesis GO:0009887 2.434454 0.001375 0.34
cell motility GO:0006928 2.410239 0.00141 0.298857
striated muscle contraction GO:0006941 1.781977 0.002482 0.4605
regulation of body fluids GO:0050878 1.602872 0.003043 0.501778
angiogenesis GO:0001525 1.40132 0.003982 0.5909
Microarray data for GNF human tissues study [41] was analyzed with SLEPR method to compare muscle related tissues (total 4 muscle related tissues selected: Cardiac
Myocytes, Heart, Skeletal Muscle, Smooth Muscle) as Inclusion/Target tissue to the rest of tissues (74 other tissues) as Exclusion/Background class for testis-specific GO
biological processes, using one-side MADe method for selection of highly expressed genes as sample-level differentiated genes (see Materials And Methods section).
1000 permutations were performed.
doi:10.1371/journal.pone.0003288.t009
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approach may miss important aspects of biology.
Interestingly, Chinnaiyan’s group has hypothesized that many
oncogenes may exhibit marked over-expression only in a subset
of tumor samples and traditional analysis methods such as t-
statistic has limitation to detect them [48]. Consequently, they
proposed a novel method, commonly known as ‘‘Cancer outlier
profile analysis’’ or COPA, which can effectively uncover such
oncogene outlier expression profile [48]. Such efforts have been
improved and extended by a few other groups [49–52]. These
methods are great renovations over the conventional t-statistic
based or other gene-level consistency-based methods. However,
since these methods mainly focus on extremely expressed genes
or outliers and still consider all of their statistics at gene-level,
although they may use other genes’ data to estimate the
significance of their statistics, they are still considered as gene-
level approaches.
In the current study, we explored a new method termed
SLEPR, which considers the possibility that genetic impacts
leading to class distinctions can occur, and consequently be
measured, at the pathway level rather than at the individual gene
level. Our method is motivated not only similarly as COPA
methods intended for oncogene outliers occurred in only a subset
of tumor samples, but also more importantly by the observation
that many diseases are not simply caused by single genes, including
complex diseases such as cancers, heart diseases, and hypertension,
which have been shown to be caused by mutations in multiple
genes in the same or related pathways or caused by single but
different genes in individuals that causing biological changes in the
same or related pathways among the population [53–56]. This is
Table 10. Top ranked terms in SLEPR analysis results for a well-studied prostate cancer dataset.
GSEA_TermName GSEA_TermID Combined_Ranking Permutated_P_Val FDR q_Val
Sixty-seven genes commonly upregulated in
cancer relative to normal tissue, from a
meta-analysis of the OncoMine gene
expression database
CANCER_NEOPLASTIC_META_UP 7.312481 5.43E-07 0.000111
Genes downregulated in response to
glutamine starvation
PENG_GLUTAMINE_DN 6.578343 5.43E-07 6.25E-05
These are genes identified by simple statistical
criteria as differing in their mRNA expresssion
between WTs and fetal kidneys LOW
LI_FETAL_VS_WT_KIDNEY_UP 5.961163 5.43E-07 0.00004
Genes 2fold upregulated by insulin ROME_INSULIN_2F_UP 5.905375 5.43E-07 3.7E-05
Genes up-regulated by MYC in P493-6 (B-cell) SCHUMACHER_MYC_UP 5.762658 5.43E-07 3.45E-05
Genes highly expressed in hepatocellular
carcinoma with poor survival.
HCC_SURVIVAL_GOOD_VS_POOR_DN 5.449725 5.43E-07 2.94E-05
A well studied prostate cancer dataset [42,43] was analyzed with SLEPR method. SLEPR method used the 25 tumor samples as Inclusion/Target class compared to 9
nonmalignant tissues as Exclusion/Background class for GSEA annotated terms, by two-sided MADe method for selection of both highly and lowly expressed genes as
sample-level differentiated genes. Only top ranked functional terms were shown in the table (the chromosomal location-based annotation terms were taken out for
simplicity). 1000 permutations were performed.
doi:10.1371/journal.pone.0003288.t010
Table 11. Top ranked terms in GSEA analysis results for a well-studied prostate cancer dataset.
GSEA_TermName GSEA_TermID ES NES NOM p-val FDR q-val FWER p-val
Genes up-regulated by MYC in P493-6 (B-cell) SCHUMACHER_MYC_UP 0.6769 2.043 0.001* 0.031466 0.039
Genes overexpressed in polyclonal plasmablastic cells
(PPCs), mature plasma cells isolated from tonsils (TPCs),
and mature plasma cells isolated from bone marrow
(BMPCs), as compared to B cells purified from
peripheral blood (PBBs) and tonsils (TBCs)
TARTE_PC 0.6101 1.954 0.0019193 0.07472 0.144
Genes downregulated in response to glutamine
starvation
PENG_GLUTAMINE_DN 0.4842 1.939 0.001** 0.058919 0.167
Genes downregulated in response to leucine starvation PENG_LEUCINE_DN 0.5067 1.911 0.001** 0.066378 0.238
Downregulated in HL-60 promyeloid leukemic cells
after treatment with the cytotoxic drug cantharidin
CANTHARIDIN_DN 0.6218 1.903 0.001* 0.059042 0.26
Genes downregulated in response to rapamycin
starvation
PENG_RAPAMYCIN_DN 0.5000 1.891 0.0020576 0.060076 0.309
Sixty-seven genes commonly upregulated in cancer
relative to normal tissue, from a meta-analysis of the
OncoMine gene expression database
CANCER_NEOPLASTIC_META_UP 0.6634 1.883 0.0042105 0.058265 0.335
A well studied prostate cancer dataset [42,43] was analyzed with GSEA method (Using the newest version (v2.0.1) GSEA tool [24]). GSEA compared the tumor samples to
the nonmalignant tissues. Only top ranked functional terms were shown in the table (the chromosomal location-based annotation terms were taken out for simplicity,
the full ranked list can be obtained from table S7). 1000 permutations were performed. **: p-value(s) is adjusted to p=1/number of permutation for p=0 according to
GSEA manual.
doi:10.1371/journal.pone.0003288.t011
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level consistency that traditional methods are based on.
In order to evaluate inter-sample consistency at the pathway-
level, we introduce a new concept: sample-level differentiated
genes (SLDGs). Unlike conventional approaches for gene-level
differentiated genes, which use data from the sample population of
one class compared to those of the other class, the SLDGs are
based on the data of each individual sample from both sides of the
contrasted class compared to the Exclusion/Background class. We
make no assumptions of the data distribution and use MADe, a
factored Median Absolute Deviation (MAD), which has more
robust statistics compared to standard deviation-based statistics
and is largely unaffected by the presence of extreme values [57–
58] (see Materials And Methods section). Since we select SLDGs
from the higher and/or lower ends (distance of MADe from the
median) of that genes’ data distribution in the Exclusion/
Background class sample, the method should capture both gene-
level and pathway-level differential effects. It should be noticed
that our SLDGs are different from the outlier genes selected by
COPA methods mentioned early in that SLDGs are sample-wise
genes called on behalf of each sample, whereas outlier genes from
COPA methods are called population-wise in spite of considering
the occurrence of outlier genes in only a subset of population. The
second difference is that the SLDGs not only include outliers as
conventionally defined, but also cover high and/or low end of
expressers as the basis for the next-step analysis of SLEPR.
It is possible that when SLEPR method selects SLDGs with
1XMADe as the cutoff, the chance of outlier data leading to
mistakenly selecting genes would be higher. The reason that we did
not filter out the outlier data in advance is that we believe some
outliers have biological relevance, just like what the COPA methods
seek for, which is not caused by experimental issues. Simply filtering
these genes out before evaluating their biological relevance could
lead toloss ofimportant information.Sincewe use theFisher’sexact
test based enrichment method for pathway-level consistency
analysis, the outliers could work together with other relevant genes
of high and/or low end expressers to contribute to enrichment
scores, which otherwise would be reduced to less significant levels.
We have tested our method with a series of constants (0.5, 0.75,
1.25, 1.5; Table 5; even 1.75, data not shown) that multiply MADe
as the final cutoffs for selecting sample-level differentiated genes
rather than the default setting of 1.0 and our MADe selections are
quite stable in the final pathway-ranking results in that they pick
up the same set of terms as highly or top ranked terms. This
suggests that the SLEPR method is quite stable in terms of the
cutoff for selection of genes, which is in contrast to the
conventional ORA method using a single summary gene list as a
starting point that has been claimed to be sensitive to the cutoff
used for getting the gene lists [31].
Thus, sample-level differentiated genes represent a robust input
starting point for subsequent SLEPR enrichment analysis using
Fisher’s exact test as the basis for discrimination of changed
pathways. The derived enrichment score for each sample from both
sides of thecontrastedclasses wasused to evaluate the pathway-level
consistency. We further evaluated the consistency across samples
between both Inclusion and Exclusion classes for the best pathway
that was present at a higher frequency and higher enrichment
magnitudes in samples of the Inclusion/Target class but not in
Exclusion/Background class, or with less frequency or lower
enrichment magnitudes. This is the basic rationale that we used
to set up the pathway-ranking algorithm in SLEPR method.
As we have shown in example datasets, the SLEPR method
worked quite well and was able to not only reproduce the
previously analyzed and experimentally validated results (the
human DM2 dataset, Table 1,2; prostate cancer dataset, Table 10)
or generated analysis results that are consistent with biologically
relevant expectations (the GNF tissue dataset, Table 6, 7 and 9;
prostate cancer dataset, Table 10), but also may have provided
more opportunity to study those highly ranking terms using the
pathway-level differentiated genes derived from the corresponding
sample-level differentiated genes. We also suggest that one could
even rank these genes for their possible relevance to a phenotype
of interest between the contrasted classes as we showed for our
pathway-ranking algorithms (Figure S1, Table S3, also see
Materials And Methods section).
As a comparison with other group test methods such as the
GSEA method [23], we carefully selected three datasets, which are
well characterized public datasets that either have had the results
validated (the human DM2 dataset, prostate cancer dataset
[23,42]) or have clear biological expectations based on the nature
of the studies they were derived from (the GNF human tissue
dataset [41]). Thus, the analysis results from these datasets can be
easily interpretated and compared for different analysis methods.
In addition, we are confident the choice of these well-character-
ized data should be better than any simulated data or synthetic
datasets, since they carry natural noise levels from both
experimental and biological variations. In fact, we did a couple
of tests using synthetic databases derived from randomly selected
genes forming artificial gene sets mixed with a real gene set and
SLEPR worked very well in these cases (Table S5).
We have found that in all the head-to-head comparisons with
the GSEA method, our SLEPR method consistently did a better
job or got at least compatible results with those from the GSEA
method (Table 1, 2 vs. 3, 4; 6 vs. 8; 10 vs.11). First of all, our
method was more sensitive than the GSEA method at uncovering
biological themes with higher significance in general. Such a
conclusion was drawn by comparing p-values, FDR q-values and
rankings obtained by both methods for the sense of relative
significance considering all the terms in the results, taking into
account the difficulty in directly comparing the p-values and FDR
q-values derived from the two quite different methods with
differences in algorithms and rationales. For example, the highly
ranked term ‘‘oxidative phosphorylation’’ has higher significance
revealed by SLEPR than by GSEA as mentioned in the Result
section (Table 1–4). Secondly, as evident in Table 1 to 4 and 10
to11, our SLEPR method was more powerful than the GSEA
method in terms of finding more relevant terms with a broader
scope for biological relevance functionally linked to the phenotypes
under study. For example, 5 related terms were consistently
uncovered by SLEPR (Table 1, 2) compared to only 1 or 3 of them
that were found by GSEA with the same class setting, respectively
(Table 3, 4). Thirdly, our method was consistent and powerful in
the analysis result with flexible inclusion of relatively diversified
but related samples into analysis, especially when the intermediate
class samples were included. For example, as evident in Table 1 to
4, particularly in Table 1 vs. 3, where DM2 and IGT were pooled
together as one class in class comparison with NGT (NGT vs.
DM2+IGT) based on the observation that the intermediate class
IGT is more similar to DM2 in phenotype than NGT, SLEPR has
consistently uncovered many of the relevant functional terms
similar to class comparison of NGT vs. DM2 (Table 1, 2), whereas
GSEA failed to do so (Table 3, 4). In addition, SLEPR was able to
find consensus of underlying functions within related but different
samples, which can be only ‘‘loosely’’ defined as one class (e.g.,
testis-related tissue in Table 6 and 8; muscle-related tissues in
Table 9; neural-related tissue in Table S6). This would give
SLEPR more flexibility and power to overcome the variations and
naturally existing noise in biology samples to find the major
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the RESULTS section, the appearance of FDR ‘‘gap’’ (the sharp
rise) in SLEPR results implicated a potential statistical threshold
that may have biological relevance, which may help users
distinguish the significant terms from non-significant ones and
easily draw a line to select the terms for further investigation.
Fifthly, in contrast to the potential bias in GSEA method that
higher enrichment scores were assigned preferentially to gene sets
of large size [40], no such bias exists in SLEPR method (Figure
S4). Lastly, since our SLEPR method begins with sample-level
differentiated genes in contrast to the gene-level consistency-based
gene ranking in the GSEA method, SLEPR is designed to capture
the sample-wise gene-level changes taking into account individual
variations and specificity over the population and obviously would
cover more possible gene-level changes in the population with the
phenotype of interest. This is another benefit that SLEPR is
designed to pursue. Consequently, SLEPR would be able to
retrieve more possible relevant genes as pathway-level differenti-
ated genes that may account for phenotype of interest, which
GSEA or other group test methods may have missed due to the
fact that they only consider the genes with better across-sample
data behavior (e.g., SNR on top of mean and standard deviation of
both contrasted classes in GSEA [32]; correlated expression
pattern [33]; fold change or ratio in between two classes [27]).
It is very important to emphasize that SLEPR is neither a simple
extension of GSEA or other group test methods with similar
analysis goals nor COPA methods specifically looking for outlier
genes, but rather a novel pathway analysis method in terms of its
unique concepts and methodology. Unlike others, SLEPR does
not attempt to rank the genes or derive conventional differentiated
genes at the beginning; instead, it just collects the potential genes
for each sample that behave unusually compared to the
population. Then SLEPR ranks the pathways or terms based on
how consistent the enrichment levels of the terms amongst the
selected sample-level differentiated genes of each sample. It is
SLEPR that points out the new concept for the analysis: pathway-
level consistency as the basis for analysis, which is not considered
in any of the other analysis methods including GSEA.
In conclusion, the SLEPR method represents a novel way to
analyze high throughput data through pathway-level consistencies
that have been proven to be effective in uncovering biological
themes. Since sample-level differentiated genes can be selected
from datasets measuring changes at different levels of regulation,
including transcription, protein expression, and phosphorylation
occurring in the same individual samples, all HTP data measuring
these changes in the systems biology era can be integrated and
included in SLEPR method. Furthermore, we feel that using
sample-level rather than gene-level enrichment as a starting point
may represent a much more robust and versatile approach for
integration of data from multiple sources as new technologies
advance the ability to assess regulatory networks at multiple levels.
Materials and Methods
Three public microarray datasets [23,41,42] were obtained
from the original publications and used for purpose of demon-
stration for SLEPR method. All the described procedures for the
SLEPR method are implemented into and as a part of newly
developed pathway pattern extraction pipeline in the original WPS
program developed previously [4], which can be downloaded from
the WPS website (http://www.abcc.ncifcrf.gov/wps/wps_index.
php). The details and program interface of the pathway pattern
extraction pipeline in WPS program are described elsewhere in a
separate manuscript (Yi and Stephens unpublished work). The
following sections are details of those procedures, which were also
schematically illustrated in Figure 1.
Inclusion/Target Class versus Exclusion/Background Class
For a given dataset intended for contrast studies (e.g., NGT vs.
IGT+DM2; tumor vs. normal tissues; muscle tissues vs. other
tissues), we separated all of the samples from the dataset into two
classes representative of interested contrast: Exclusion/Back-
ground class E (e.g., normal tissues) as the class for background
of data measurement and the interested class: Inclusion/Target
class I (e.g., tumor tissues) as the target sample group to make
comparison with Exclusion/Background class. E and I is
exchangeable and also do not have to cover all the samples in
datasets, dependent upon the questions to address. The same
sample can not be selected into E and I classes at the same time.
Therefore, if TI as total number of samples from Inclusion class I
and TE as number of samples from Exclusion class E, and there
are total T samples in dataset. Thus, we have TI+TE,=T.
Select Sample-Level Differentiated Genes for Each
Sample in Dataset
For each single gene k in a dataset, its data in sample j is denoted
as Dk,j (k: gene k; j: sample j in the dataset, either in Class I or Class
E). To decide whether gene k is a sample-level differentiated gene
for sample j, we first used data of gene k in samples within
Exclusion/Background class E as background distribution of data
to create a cutoff threshold Ck for gene k, where we have
Ck=MADe({Dk,j}), where j=1,2,… TE; TE is number of samples in
Class E in the dataset.
Function MADe() is defined as following: for n values xi
(i=1,2,..n) in a data set X:
MADe xi fg ðÞ
~ 1:483 1 MAD xi fg ðÞ
~ 1:483 1 median xi{median X ðÞ jj fg ðÞ
where the inner median median(X) is the median of the set X and
the outer median is the median of the n absolute values of the
deviations about the inner median. MAD is conventional Median
Absolute Deviation and 1.483 is the scaling factor, which make
MADe comparable with a SD (Standard Deviation), although
MADe is more robust than SD and unaffected by the presence of
extreme values or outliers [57–58]. We also define median
expression level Mk for gene k for samples in Exclusion class E as:
Mk~median Dk,j
     
where j=1,2,… TE; TE is number of samples in class E in the
dataset.
There are two MADe-based methods for selecting sample-level
differentiated genes: one-sided MADe method and two-sided
MADe method. The one-sided MADe method intends to only
select sample-level differentiated genes from one direction of
changes (e.g., only up-regulated genes or only down-regulated
genes) in each sample. In contract, the two-sided MADe method
intends to select sample-level differentiated genes from both
directions of changes (e.g., pooled highly expressed genes and
lowly expressed genes together) in each sample.
For one-sided MADe method, there are two options for
selecting genes: higher side (right-side) or lower side (left side)
sorting options, which will select only highly expressed (e.g., up-
regulated) genes, or only lowly expressed (e.g. down-regulated)
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distribution of Exclusion/Background class, respectively. For
higher side sorting option, considering gene k, if and only if
Dk,m.=Mk+Ck, gene k will be selected as a sample-level
differentiated genes (e.g., highly expressed) for sample m. For
lower side sorting option, considering gene k, if and only if
Dk,m,=Mk2Ck, gene k will be selected as a sample-level
differentiated gene (e.g., lowly expressed) for sample m; where
sample m is one of the selected samples in the dataset (either a
sample from Class I with TI samples or Class E with TE samples).
For two-sided MADe method, considering gene k, either if
Dk,m.=Mk+Ck or if Dk,m,=Mk2Ck, gene k will be selected as
sample-level differentiated gene (e.g., highly expressed or lowly
expressed ) for sample m, where sample m is one of the selected
samples in the dataset (either a sample from Class I with TI
samples or Class E with TE samples). This method will pool
together the genes that have changed at either direction (e.g.,
highly or lowly expressed) into sample-level differentiated lists.
Each time sample-level differentiated genes are selected, an
intermediate result file can be created, in which a similar binary
data matrix with value of either 1 or 0 was generated like the
original data matrix, except that for each data point in the original
matrix, say, a data point for gene g and sample s, the data was
transformed to either 1 if gene g was selected as sample-level
differentiated genes for sample g, or 0 if not. The interface for
creating such an intermediate result file is implemented into WPS
[4] and described in a separate manuscript (Yi and Stephens
unpublished work). Such an intermediate result file is useful if one
wants to further pursue the importance of each of the pathway-
level differentiated genes involving in the studied phenotype with
class-ranking method described as below.
Compute for Enrichment Scores for Each Sample-Level
Differentiated Genes into an Enrichment Score Matrix
Once the sample-level differentiated gene lists are sorted into
individual files in a file folder or directory using WPS program
interfaces and utilities of pathway pattern extraction pipeline
described in a separate manuscript (Yi and Stephens unpublished
work), enrichment scores can be computed in a batch mode for
each of these gene lists and merged into a stanford format file.
Briefly, Fisher’s exact test is performed based on 262 contingency
tables (whether a gene is in the given list or not vs. whether this
gene is associated with a pathway/term or not, described
previously [4] for each term for each list). All Fisher’s exact test
results are ranked based on the p-values for each list and stored as
individual files for further merging. During the merging process,
all the p-values are transformed by a formula (2Log10(p-value))
into enrichment scores, where appropriate filtering is applied,
typically, ListHits,2 or p-value.0.05 will be used to floor the
enrichment scores to 0; otherwise, 2Log10(p-value) will be the
enrichment scores. The data matrix of enrichment scores without
any flooring or filtering (i.e., original enrichment scores (2Log10(p-
value))) may be also obtained from a program interface described
in a separate manuscript (Yi and Stephens unpublished work).
Pathway-Ranking for Enrichment Score Matrix
For each term in the enrichment score matrix, let the
enrichment score of sample i in pathway or term t as ESi,t, TI as
total number of samples from Inclusion class I and TE as number
of samples from Exclusion class E.
In order to get the Pathway-ranking score for a given pathway
or term t, we need compute for two intermediate ranking scores
for each term t: class difference ranking scores and p-value sum
ranking scores. Class difference ranking scores reflect the
difference in the percentages of samples in class I and class E
with significant enrichment scores. p-value sum ranking scores
reflect the difference in the magnitude of the enrichment scores in
samples of class I and samples of class E.
Cfc is defined as the Cutoff for class difference ranking score, as
default, Cfc=2log10(0.05)=1.3 (one can change the default in
program interface to other desired value). First, we compute for
class difference ranking score CDR for pathway or term t, which is
defined as CDRt, we have:
CDRt~NE S i,twCfc,i[I ðÞ
 
TI{NE S j,twCfc,j[E
    
TE
Where N(ESi,t.Cfc, iMI) refers to the number of samples in class I
with enrichment score larger than the Cfc; and N(ESj,t.Cfc, jME)
refers to the number of samples in class E with enrichment score
larger than the Cfc.
Then, we compute for p-value sum ranking scores for pathway













ESi,t refers to the sum of enrichment scores for term t of
all samples in class I and
P
j[E
ESj,t refers to the sum of enrichment
scores for term t of all samples in class E. Thus, to compute the
pathway-ranking score for a given pathway or term t, which
referred as PRt, we have:
If both CDRt and PSRt are less than 0, PRt is computed as
PRt=(21)*CDRt*PSRt; otherwise, PRt is computed as:
PRt=CDRt*PSRt.
Estimation of Significance of Ranked Pathways/Terms
The statistical significance of a given pathway ranking score PRt
for a given pathway or term t is assessed with permutated p-value
using permutation testing of class assignments of each sample from
both Inclusion and Exclusion classes (e.g., whether a sample has a
phenotype of DM2 versus NGT in the human type 2 diabetes
mellitus (DM2) dataset [23]). Briefly, we permutate the sample
labels among total selected samples including both class I and class
E. For each permutation, we re-calculate pathway-ranking score
for each term t as permutated PRt. This procedure was repeated
1000 (default setting) or more times. The permutated p-value for
each term t is calculated as the fraction of random trials resulting
in permutated pathway-ranking scores no less than PRt. The FDR
q value is also calculated based on this null distribution derived
from permutation as followed: to compute an FDR q value, for a
given pathway-ranking score PRt, the FDR is the ratio of the
percentage of all pathway-ranking scores derived from the
permutated data, which are no less than PRt, divided by the
percentage of observed pathway-ranking scores derived from the
original data, which are no less than PRt. Because such
permutation tests randomize the class assignments of samples
from both sides of contrasted classes, it is a test of the dependence
of the actual class assignment for each individual sample, which is
characteristic of the phenotype under study.
Retrieval and Ranking of the Associated Genes for
Significant Ranked Terms as Pathway-Level Differentiated
Genes
The ranked pathways with significant permutated p-values,
FDR, and/or rankings may be used for retrieval of their associated
SLEPR Pathway Ranking Method
PLoS ONE | www.plosone.org 14 September 2008 | Volume 3 | Issue 9 | e3288genes from the sample-level differentiated genes in samples of
Inclusion class. The retrieval can be easily done using newly
developed WPS pipeline interface for pathway-level pattern
extraction, described in a separate manuscript (Yi and Stephens
unpublished work). The retrieved genes can be ranked in a way
similar to the class ranking method used for pathway ranking,
using the subset of data for these genes derived from the
intermediate result file created when selecting the sample-level
differentiated genes as described above.
Within the retrieved associated genes, we compute for class
difference ranking score CDRG for gene g, which is defined as
CDRGg, and each transformed value TV (i.e. 1 or 0) in the data
matrix of an intermediate result file referred as TVs,g for sample s
and gene g, then we have:
CDRGg~NT V i,g~1,i[I
    
TI{NT V j,g~1,j[E
    
TE
Where N(TVi,g=1,iMI) refers to the number of samples in class I
with transformed value in the intermediate file equal to 1; and
N(TVj,g=1, jME) refers to the number of samples in class E with
transformed value in the intermediate file equal to 1.
We define these genes with CDRG larger than 0 as pathway-
level differentiated genes, which may potentially represent the
whole repertoire of alternations occurring at gene level within the
engaged pathway in association with the class contrast or
compared phenotypes. Such ranking of pathway-level differenti-
ated genes can be used for evaluating the significance or the
probability of the involvement of these genes related to the
interested phenotype in the dataset under study.
Supporting Information
Figure S1 Sample-wise gene-level variations shown by the
heatmap of z-scores for pathway-level differentiated genes, which
are associated with one of the top terms (Oxidative Phosphory-
lation) from the SLEPR result in Table 1. The z-scores of these
genes were computed using all samples from both Inclusion and
Exclusion classes, and were displayed in the heatmap using color
gradient for their values as red for positive z-scores and green for
negative z-scores, black for scores of 0. The z-scores are calculated
on each gene basis. For each sample, the z-score (also referred as
standard score sometime) of an intended gene is derived by
subtracting the population mean of this gene from the original
data of the corresponding sample of this gene and then dividing
the difference by the population standard deviation of this gene. In
general, a positive z-score indicates a relatively higher expression
level of a gene in the corresponding sample over the sample
population for this gene; negative for a lower expression; 0 for
average expression.
Found at: doi:10.1371/journal.pone.0003288.s001 (1.41 MB TIF)
Figure S2 Heatmap of call values for sample-level differentiated
genes, which are associated with one of the top terms (Oxidative
Phosphorylation) from the SLEPR result in Table 1. The call value
is 1 if the gene is called as sample-level differentiated genes for the
corresponding sample, 0 if not. The genes were ranked in a way as
described in Materials And Methods Section, and were displayed
in the heatmap in the order of ranks from top to bottom with
higher ranked genes at the top.
Found at: doi:10.1371/journal.pone.0003288.s002 (1.17 MB TIF)
Figure S3 Sample-wise gene-level variations shown by the
heatmap of Z-scores for sample-level differentiated genes, which
are associated with the No. 1 (Muscle contraction) and No. 2
(Muscle development) terms from the SLEPR result in Table 9.
The z-scores of these associated genes were computed using all
samples from both Inclusion and Exclusion classes, and were
displayed in the heatmap using color gradient for their values as
red for positive z-scores and green for negative z-scores, black for
scores of 0.
Found at: doi:10.1371/journal.pone.0003288.s003 (1.37 MB TIF)
Figure S4 No bias for the SLEPR ranking scores vs. sizes of gene
sets. A pdf file with several plots showing no bias for the SLEPR
ranking scores vs. sizes of the gene sets: for distribution of SLEPR
pathway ranking scores vs. gene set sizes (with different gene set
size windows) and histogram distribution of gene set sizes for data
in Table S2, Table S4, and Table S6 (for all terms or different
numbers of top ranked terms in the tables).
Found at: doi:10.1371/journal.pone.0003288.s004 (1.92 MB
PDF)
Table S1 The complete list of result of GSEA analysis result for
NGT vs. IGT+DM2 comparison, which has the top ranked terms
shown in Table 3
Found at: doi:10.1371/journal.pone.0003288.s005 (0.19 MB
XLS)
Table S2 The complete list of result of SLEPR analysis result of
GSEA annotations for NGT vs. IGT+DM2 comparison with one-
side MADe option for highly expressed genes in NGT, which has
the top ranked terms shown in Table 1.
Found at: doi:10.1371/journal.pone.0003288.s006 (0.33 MB
XLS)
Table S3 The complete list of ranked pathway-level differenti-
ated genes of the No. 1 term (Oxidative Phosphorylation) in
Table 1. The call values for sample-level differentiated genes of
these genes are also included in the file.
Found at: doi:10.1371/journal.pone.0003288.s007 (0.06 MB
XLS)
Table S4 The complete list of SLEPR analysis result of GSEA
annotations for NGT vs. DM2 comparison with two-side MADe
option for highly or lowly expressed genes in NGT.
Found at: doi:10.1371/journal.pone.0003288.s008 (0.30 MB
XLS)
Table S5 The complete list of SLEPR analysis result of a
synthetic database that consisted of 2000 randomly selected gene
sets (with matched size of gene set) mixed with the known gene set
of ‘‘Oxidative Phosphorylation’’ from MSigDB. NGT versus
IGT+DM2 class contrast was used with one-side MADe option for
highly expressed genes in NGT.
Found at: doi:10.1371/journal.pone.0003288.s009 (0.22 MB
XLS)
Table S6 The complete list of SLEPR analysis result of GO
biological processes for comparison of neural or brain-related
tissues vs. other tissues with one-side MADe option for highly
expressed genes in neural or brain-related tissues.
Found at: doi:10.1371/journal.pone.0003288.s010 (0.28 MB
XLS)
Table S7 The complete list of result of GSEA analysis result for
tumor vs. normal comparison, which has the top ranked terms
shown in Table 11
Found at: doi:10.1371/journal.pone.0003288.s011 (0.16 MB
XLS)
Table S8 The complete list of SLEPR analysis result of KEGG
pathways for comparison of tumor vs. normal with two-side
MADe option for highly or lowly expressed genes in tumors.
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XLS)
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